300 results on '"Caruso, Cristiano"'
Search Results
2. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
3. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
4. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus
5. Evaluation and Updated Classification of Acute Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAID-Exacerbated or -Induced Food Allergy
6. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
7. The New Paradigm: The Role of Proteins and Triggers in the Evolution of Allergic Asthma
8. The Combined Use of Chronological and Morphological Criteria in the Evaluation of Immediate Penicillin Reactions: Evidence From a Large Study
9. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life
10. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study
11. RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.
12. Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC).
13. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
14. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
15. The last step to achieve barrier damage control
16. Patient and Physician Perspectives on Mepolizumab Treatment in Severe Asthma: Data From the REALITI-A Study
17. Severe asthma: One disease and multiple definitions
18. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
19. Evaluating Immediate Reactions to Cephalosporins: Time Is of the Essence
20. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
21. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
22. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)
23. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study.
24. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis
25. Tolerability of Cefazolin and Ceftibuten in Patients with IgE-Mediated Aminopenicillin Allergy
26. The Role of Gut Microbiota and Leaky Gut in the Pathogenesis of Food Allergy
27. Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
28. Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life
29. The Role of Gut Microbiota and Leaky Gut in the Pathogenesis of Food Allergy.
30. Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
31. Are Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from 8 Italian Centers
32. Immunoglobulin Free Light Chains in Severe Asthma Patient: could they be a new biomarker?
33. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins
34. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
35. Switching Biological Therapies in Severe Asthma
36. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
37. High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study
38. Delayed hypersensitivity to dimethyl fumarate: report of one case and literature review
39. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell–mediated hypersensitivity to penicillins
40. Additional file 3 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
41. Additional file 4 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
42. Additional file 1 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
43. Additional file 5 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
44. Additional file 2 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
45. Switching Biological Therapies in Severe Asthma
46. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins
47. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins
48. Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
49. Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis
50. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.